A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

ClinicalTrials.gov ID: NCT01083615

Public ClinicalTrials.gov record NCT01083615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer

Study identification

NCT ID: NCT01083615
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Achieve Life Sciences; Industry
Enrollment: 14 participants

Conditions and interventions

Conditions

Interventions

custirsen sodium Drug
isotonic, 0.9% sodium chloride Drug
docetaxel Drug
cabazitaxel Drug
prednisone Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2010
Primary completion: Feb 28, 2013
Completion: Feb 28, 2013
Last update posted: Oct 11, 2016

2010 – 2013

United States locations

U.S. sites: 20
U.S. states: 19
U.S. cities: 20

Facility	City	State	ZIP	Site status
Not listed	La Verne	California	91705	—
Not listed	Fort Lauderdale	Florida	33308	—
Not listed	Tampa	Florida	33612	—
Not listed	Honolulu	Hawaii	96813	—
Not listed	Urbana	Illinois	61801	—
Not listed	Metairie	Louisiana	70006	—
Not listed	Baltimore	Maryland	21201	—
Not listed	Burlington	Massachusetts	01805	—
Not listed	Detroit	Michigan	48201	—
Not listed	Kansas City	Missouri	64132	—
Not listed	Omaha	Nebraska	68130	—
Not listed	Las Vegas	Nevada	89169	—
Not listed	Syracuse	New York	13210	—
Not listed	Raleigh	North Carolina	27607	—
Not listed	Canton	Ohio	44718	—
Not listed	Oklahoma City	Oklahoma	73120	—
Not listed	Portland	Oregon	97239	—
Not listed	Columbia	South Carolina	29209	—
Not listed	Memphis	Tennessee	38120	—
Not listed	Tyler	Texas	75701	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01083615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 11, 2016 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01083615 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →